Precision Biosciences

The company has contracted with EKG Sales Associates for life science lead generation and hired two new sales directors. 

The North Carolina-based firm plans to use the money to continue development of its Arcus genome editing platform.

NEW YORK (GenomeWeb News) – Precision BioSciences and Nova Synthetix today announced a deal for the use of each other's technologies to generate "non-GM," ricin-free castor plants.

NEW YORK (GenomeWeb News) – Precision BioSciences and Agrivida have struck an agreement to use Precision Bio's genetic modification technology to develop traits in corn that can improve animal nutrition for the dairy and beef industries.

NEW YORK (GenomeWeb News) – Precision BioSciences and Cellectis announced Thursday that they have settled patent litigation related to genome engineering technology and have agreed to cross-license certain patents.

NEW YORK (GenomeWeb News) – Precision BioSciences said today that it is suing Lonza Group and a number of its affiliates for patent infringement.

NEW YORK (GenomeWeb News) – Precision BioSciences today claimed victory in a lawsuit filed against the company by Cellectis alleging patent infringement.

NEW YORK (GenomeWeb News) – Illumina disclosed in its quarterly filing with the US Securities and exchange Commission that it paid a total consideration of $95.5 million for its acquisition of BlueGnome in July.

NEW YORK (GenomeWeb News) – Life Technologies this week said that it will invest $20 million in expanding its cell culture facility in Inchinnan, Scotland.

Pages

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.